Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 24, 2025
Safety, Tolerability, and Immunogenicity of Revaccination with mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years
Jaya Goswami, Jose F Cardona, Jorge Caso, et al.
Infection
|
January 17, 2023
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial
Matthew G Johnson, Julie M Strizki, Michelle L Brown, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 4, 2025
Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18-59 Years
Erick F Mayer, Ann R Falsey, Rebecca Clark, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 14, 2020
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
Ivan Titov, Richard G Wunderink, Antoine Roquilly, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 11, 2019
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
Johann Motsch, Cláudia Murta de Oliveira, Viktor Stus, et al.
The Lancet. Infectious Diseases
|
November 28, 2024
Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial
Jaya Goswami, Jose F Cardona, Denise C Hsu, et al.
NEJM Evidence
|
February 6, 2024
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults
Yoseph Caraco, Gordon E Crofoot, Pablo Andres Moncada, et al.
Hepatology (Baltimore, Md.)
|
February 24, 2018
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial
Graham R Foster, Kosh Agarwal, Matthew E Cramp, et al.
The New England Journal of Medicine
|
December 16, 2021
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
Angélica Jayk Bernal, Monica M Gomes da Silva, Dany B Musungaie, et al.
The Journal of Infectious Diseases
|
June 18, 2024
Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults
Jaya Goswami, Abdullah H Baqui, Pablo A Doreski, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 24, 2025
Safety, Tolerability, and Immunogenicity of Revaccination with mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years
Jaya Goswami, Jose F Cardona, Jorge Caso, et al.
Infection
|
January 17, 2023
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial
Matthew G Johnson, Julie M Strizki, Michelle L Brown, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 4, 2025
Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18-59 Years
Erick F Mayer, Ann R Falsey, Rebecca Clark, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 14, 2020
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
Ivan Titov, Richard G Wunderink, Antoine Roquilly, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 11, 2019
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
Johann Motsch, Cláudia Murta de Oliveira, Viktor Stus, et al.
The Lancet. Infectious Diseases
|
November 28, 2024
Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial
Jaya Goswami, Jose F Cardona, Denise C Hsu, et al.
NEJM Evidence
|
February 6, 2024
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults
Yoseph Caraco, Gordon E Crofoot, Pablo Andres Moncada, et al.
Hepatology (Baltimore, Md.)
|
February 24, 2018
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial
Graham R Foster, Kosh Agarwal, Matthew E Cramp, et al.
The New England Journal of Medicine
|
December 16, 2021
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
Angélica Jayk Bernal, Monica M Gomes da Silva, Dany B Musungaie, et al.
The Journal of Infectious Diseases
|
June 18, 2024
Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults
Jaya Goswami, Abdullah H Baqui, Pablo A Doreski, et al.
Page
of 3